Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial ...

Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and Drug Administration (FDA) in H2 2025 targeting the U.S. approval of ...

Pfizer Media Contact: +1 (212) 733-1225 PfizerMediaRelations@Pfizer.com Pfizer Investor Contact: +1 (212) 733-4848 IR@Pfizer.com Arvinas Media Contact: ...

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer. May 31, 2025 8:00 AM ET Pfizer Inc. ...

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer. News provided by.

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients ...